TPN-101, a potent nucleoside reverse transcriptase inhibitor that specifically inhibits the LINE-1 reverse transcriptase.
Transposon Therapeutics announced that The Alzheimer’s Drug Discovery Foundation invested in their new Alzheimer’s Disease treatment TPN-101. The biotechnology companyspecializes in orally administered therapy treatments for neurodivergent and aging-related diseases,announced they are now expecting the investment to help advance developments of TPN-101.
What are recent advancements in Alzheimer's research?
TPN-101, a potent nucleoside reverse transcriptase inhibitor that specifically inhibits the LINE-1 reverse transcriptase, is being developed for people with ALS, progressive supranuclear palsy (PSP), and Alzheimer's disease.2
Transposon anticipates for TPN-101 to begin Phase 2 clinical trials to study the effects of TPN-101 in patients diagnosed with AD by the end of 2025.
This, however, is not the first tests of TPN-101 in clinical trials. TPN-101 was previously selected for Phase 2/3 HEALY ALS Platform Trial back in May of 2025. The HEALY ALS Platform Trial is a multicentered, double-blind, placebo-controlled trial for ALS that allocates the evaluation of multiple products simultaneously.
"We are delighted to be partnering with the Alzheimer's Drug Discovery Foundation to rapidly advance the development of TPN-101 for the treatment of Alzheimer's disease," said Dennis Podlesak, Chairman and Chief Executive Officer of Transposon Therapeutics. "Based on the positive results of our recently completed Phase 2 studies of TPN-101 in both PSP and ALS, we believe TPN-101 has the potential to provide a critically needed treatment option for a wide range of neurodegenerative diseases, including Alzheimer's, ALS, and PSP."1
During TPN-101’s previous Phase 2 trials, it was discovered that the treatment reduced SF levels of neurofilament light chain (NfL), which is an essential biomarker of neurodegeneration within tauopathies such as progressive supranuclear palsy (PSP) and AD.
In the recently completed Phase 2 clinical trial of TPN-101 in patients with C9orf72-related ALS and/or frontotemporal dementia (FTD), in which the ALS population is further enriched for increased LINE-1 expression, TPN-101 treatment reduced the rate of decline of slow vital capacity in the ALS group by 50% compared to placebo after 24 weeks. Treatment with TPN-101 also showed a slowing of ALS disease progression as measured by the ALS Functional Rating Scale––Revised (ALSFRS-R). Additionally, TPN-101 was associated with reductions in key biomarkers of neurodegeneration and neuroinflammation, including neurofilament light chain (NfL), neurofilament heavy chain (NfH), and interleukin 6 (IL-6), compared with placebo. These results provide proof-of-concept for TPN-101 in all forms of ALS associated with TDP-43 pathology.2
With TPN-101’s testing providing proof of effective treatment, that TPN-101 provides to those effected by ALS but also FTD, and PSP, Transposon Therapeutics expects this newest investment to help continue their success.
Transposon additionally expressed its gratitude towards the HEALEY Therapy Evaluation Committee for previously including TPN-101 in their original Phase 2 clinical trials, which led the way to securing The Alzheimer’s Drug Discovery Foundation’s investment.
"We appreciate the endorsement of the HEALEY Therapy Evaluation Committee for inclusion of TPN-101 into the platform trial based on its novel target and Phase 2 clinical data and look forward to working with the HEALEY group to advance the development of TPN-101 in ALS," said Andrew Satlin, M.D., chief medical officer at Transposon. "TPN-101 is the first LINE-1 nucleoside reverse transcriptase inhibitor to show promise for the treatment of a range of neurodegenerative disorders for which few, if any, effective treatments are available."2
